China’s Pharmaceuticals Industry Is Growing

September 26, 2019

(The Economist) – THE GLEAMING campus of BeiGene, a biotechnology company in Beijing, has all the trappings of a well-heeled research laboratory. They include screening machines to test the 500,000 compounds in BeiGene’s library, its animal-testing quarters with 10,000 creatures—and Wu Xiaobin, who last year left a job as Pfizer’s head for China to run the Chinese firm’s domestic operations. Signs of expansion are all around—especially for research on cutting-edge treatments that include gene and cell therapies. The number of scientists working on such drugs has almost doubled since last year; more are being hired. Fresh lab space has replaced old offices. BeiGene, founded in 2010, is emblematic of China’s fast-changing pharmaceuticals industry—in more ways than one.